Confirmed Control Announced Transaction verified ConsumerDrug Delivery TechnologiesLife Sciences / Drug Delivery TechnologiesPharmaceutical Delivery Devices

Antares Pharma, Inc. acquired by Halozyme Therapeutics

Halozyme Therapeutics agreed to acquire Antares Pharma, Inc., a life sciences / drug delivery technologies brand on Apr 13, 2022. Financial terms were not publicly disclosed. The current comp implies EV / revenue of 4.9x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.

Transaction summary

Target
Antares Pharma, Inc.
Acquirer
Halozyme Therapeutics
Seller
-
Announced
2022-04-13
Geography
-
Tags
ConsumerDrug Delivery TechnologiesLife Sciences / Drug Delivery TechnologiesPharmaceutical Delivery Devices
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-06-19
Latest update
2026-06-19

Value and multiples

Price / value

Undisclosed

Transaction value

Basis: FundComb estimate

EV / revenue

4.9x

Period not stated

Basis: FundComb estimate

EV / EBITDA

-

EBITDA basis not stated

Basis: FundComb estimate

Basis

  • Financial terms were not disclosed in the public sources reviewed.
  • EV / revenue is shown as 4.9x based on the available comp inputs.
  • Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.

Source summary

No public source summary has been published for this transaction yet.